Thomas J. Herzfeld Advisors’s Charles River Laboratories CRL Stock Holding History

Thomas J. Herzfeld Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-23	Closed	-$4.51K	–	203
2023 Q3	$4.51K	Hold	23	–	–	﹤0.01%	265
2023 Q2	$4.84K	Hold	23	–	–	﹤0.01%	256
2023 Q1	$4.64K	Hold	23	–	–	﹤0.01%	239
2022 Q4	$5.01K	Buy	23 +3	+15%	+$655	﹤0.01%	233
2022 Q3	$4K	Hold	20	–	–	﹤0.01%	220
2022 Q2	$4K	Hold	20	–	–	﹤0.01%	231
2022 Q1	$6K	Hold	20	–	–	﹤0.01%	214
2021 Q4	$8K	Buy	20 +3	+18%	+$1.17K	﹤0.01%	226
2021 Q3	$7K	Hold	17	–	–	﹤0.01%	225
2021 Q2	$6K	Hold	17	–	–	﹤0.01%	248
2021 Q1	$5K	Buy	+17	New	+$4.72K	﹤0.01%	250

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Thomas J. Herzfeld Advisors's CRL Position: Q4 2023 in Review

Thomas J. Herzfeld Advisors sold out of Charles River Laboratories (CRL) in Q4 2023, closing a stake of 23 shares — an estimated $4.51K sold.

Thomas J. Herzfeld Advisors first reported a position in CRL in Q1 2021 and held it in 11 quarters. The position peaked at $8K in Q4 2021. 634 funds tracked by Wall St. Rank hold CRL as of Q4 2023.

Thomas J. Herzfeld Advisors reported no remaining Charles River Laboratories position as of Q4 2023 after selling out during the quarter.
Thomas J. Herzfeld Advisors sold 23 Charles River Laboratories shares in Q4 2023, an estimated $4.51K.
Thomas J. Herzfeld Advisors first reported a position in Charles River Laboratories in Q1 2021 and held it in 11 quarters.
Thomas J. Herzfeld Advisors's Charles River Laboratories position peaked at $8K in Q4 2021.
634 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2023.

Based on Thomas J. Herzfeld Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.